scholarly article | Q13442814 |
P50 | author | Victor Montori | Q7926167 |
Harlan M. Krumholz | Q28211478 | ||
Joseph S. Ross | Q42409824 | ||
G Caleb Alexander | Q89450189 | ||
Cynthia A Jackevicius | Q92575259 | ||
P2093 | author name string | Nilay D Shah | |
Jiaquan Fan | |||
Judy Zerzan | |||
Jennifer Ridgeway | |||
P2860 | cites work | Comparative effectiveness and safety of medications for type 2 diabetes: an update including new drugs and 2-drug combinations | Q22241134 |
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes | Q22250883 | ||
Changes in glitazone use among office-based physicians in the U.S., 2003-2009. | Q33751542 | ||
Medicaid prior-authorization programs and the use of cyclooxygenase-2 inhibitors | Q35952860 | ||
Impact of Medicaid prior authorization on angiotensin-receptor blockers: can policy promote rational prescribing? | Q36814187 | ||
Rosiglitazone and pioglitazone utilization from January 2007 through May 2008 associated with five risk-warning events | Q37240896 | ||
Impact of rosiglitazone meta-analysis on use of glucose-lowering medications. | Q41807349 | ||
Responding to an FDA warning--geographic variation in the use of rosiglitazone | Q42806869 | ||
Thiazolidinediones and the influence of media adverse reporting on prescribing attitudes in practice (TZD-IMPACT) study. | Q46020139 | ||
Physicians' prescribing responses to a restricted formulary: the impact of Medicaid preferred drug lists in Illinois and Louisiana | Q46345430 | ||
TESTING FOR SERIAL CORRELATION IN LEAST SQUARES REGRESSION. II | Q57253959 | ||
Switching From Rosiglitazone | Q57255282 | ||
What have we learnt from the rosiglitazone saga? | Q57277619 | ||
A community intervention trial to promote judicious antibiotic use and reduce penicillin-resistant Streptococcus pneumoniae carriage in children | Q74454449 | ||
Segmented regression analysis of interrupted time series studies in medication use research | Q74601008 | ||
Benefits and risks of increasing restrictions on access to costly drugs in Medicaid | Q79738054 | ||
Medicaid's prior authorization program and access to atypical antipsychotic medications | Q80281221 | ||
P433 | issue | 1 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | (RS)-rosiglitazone | Q424771 |
P304 | page(s) | 188-98 | |
P577 | publication date | 2012-01-01 | |
P1433 | published in | Health Affairs | Q260110 |
P1476 | title | State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning | |
P478 | volume | 31 |
Q34495367 | Association between unemployment rates and prescription drug utilization in the United States, 2007-2010. |
Q36728428 | Disparities in Discontinuing Rosiglitazone Following the 2007 FDA Safety Alert. |
Q44349603 | Effect of a High Dosage Opioid Prior Authorization Policy on Prescription Opioid Use, Misuse, and Overdose Outcomes. |
Q30359158 | Geographic Variation in Rosiglitazone Use Surrounding FDA Warnings in the Department of Veterans Affairs |
Q37185836 | Influence of health warnings on the use of rosiglitazone and pioglitazone in an area of Spain: A time-series study |
Q50919971 | Methodological approaches to evaluate the impact of FDA drug safety communications. |
Q38807857 | Novel Therapeutics for Diabetes: Uptake, Usage Trends, and Comparative Effectiveness |
Q35792497 | Rosiglitazone use and associated adverse event rates in Canada: an updated analysis |